Harrow, Inc.

HROW

US4158581094

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
24.82 ^USD	-0.12%		+8.86%	+121.61%

09/07	Harrow Agrees to Supply Products to Apexus Under 340B Prime Vendor Program	MT
24/06	Harrow, Inc.(NasdaqGM:HROW) added to S&P Pharmaceuticals Select Industry Index	CI

Transdel Pharmaceuticals, Inc. has Changed its Ticker to TDLP from TDLPQ

January 27, 2012 at 10:30 am IST

Effective January 27, 2012, Transdel Pharmaceuticals, Inc. changed its OTCPK stock ticker symbol to TDLP from TDLPQ.

Latest news about Harrow, Inc.

Harrow Agrees to Supply Products to Apexus Under 340B Prime Vendor Program	09/07	MT
Harrow, Inc.(NasdaqGM:HROW) added to S&P Pharmaceuticals Select Industry Index	24/06	CI
Craig-Hallum Adjusts Price Target on Harrow Health to $30 From $26, Buy Rating Maintained	21/06	MT
Harrow Provides TRIESENCE Relaunch Update	20/06	CI
Harrow, Inc. Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study	05/06	CI
Lake Street Raises Price Target on Harrow to $25 From $20, Maintains Buy Rating	03/06	MT
B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating	15/05	MT
Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours	14/05	MT
Harrow, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Harrow Names Greg Dipasquale as Senior Vice President, Head of Commercial	13/05	CI
Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	11/04	MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	22/03	MT
Top Midday Decliners	20/03	MT
Harrow, Inc. Provides Earnings Guidance for the Year 2024	20/03	CI
Transcript : Harrow, Inc., Q4 2023 Earnings Call, Mar 20, 2024	20/03
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	20/03	MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears	20/03	DJ
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03	CI
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Restore stock falls as weak tech trading drags down annual results	14/03	AN
Harrow, Inc. Announces Board of Director Appointments	29/01	CI
Harrow Health's Eye Treatment Drug Vevye Now Available in US	11/01	MT
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	11/01	CI
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye	03/01	MT

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Sector

Pharmaceuticals

Calendar

17/07/2024 - American Society of Retina Specialists Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harrow, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.82 USD

Average target price

29.15 USD

Spread / Average Target

+17.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARROW, INC.	+121.61%	88Cr
ELI LILLY AND COMPANY	+61.53%	86TCr
NOVO NORDISK A/S	+38.95%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ROCHE HOLDING AG	+5.89%	23TCr
NOVARTIS AG	+16.53%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	16TCr

Other Pharmaceuticals

Harrow, Inc.

Equities

HROW

US4158581094

Pharmaceuticals

Transdel Pharmaceuticals, Inc. has Changed its Ticker to TDLP from TDLPQ

Latest news about Harrow, Inc.

Chart Harrow, Inc.

Company Profile

Income Statement Evolution

Ratings for Harrow, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals